Smith+Nephew Sports Medicine advances procedural innovation by launching the QUADTRAC™ Quadriceps Tendon Harvest Guide System and expanded family of ULTRABUTTON™ Adjustable Fixation Devices for ACL reconstruction
LONDON, March 7, 2023 /PRNewswire/ — Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today introduced the UltraTRAC™ QUAD ACL Reconstruction Technique which consists of the new QUADTRAC Quadriceps Tendon Harvest Guide System, X-WING™ Graft Preparation System and family of ULTRABUTTON Adjustable Fixation Devices. These technologies work together to provide an innovative procedural solution, expanding Smith+Nephew’s ability to address surgeon graft preference.
The quadriceps tendon has been gaining popularity for use as a graft option for ACL reconstruction due to the advantages it offers.1-4 It is estimated that the number of US ACL procedures will surpass 350,000 cases in 2023 and continue to grow at a 5.7% CAGR.5
The QUADTRAC System is the first integrated guide-system for minimally invasive quadriceps graft harvesting.6 The system provides direct tendon visualization while enabling a controlled and reproducible technique to harvest.7-9 With the launch of the QUADTRAC System, Smith+Nephew capitalizes on the increasing use of the quad tendon graft, enabling graft visualization and harvest optimization.
“The QUADTRAC System is a simple and efficient solution to allow surgeons to harvest the quad tendon” said Dr. Scott Faucett, Centers for Advanced Orthopaedics. “Quad tendon is often the best option for patients undergoing ACL reconstruction and the guided cutting and tendon visualization during the procedure that the QUADTRAC System offers makes harvesting much easier. Plus, it enables surgeons to harvest with and without a bone plug allowing a diverse use of the system when using quad grafts in my practice.”
Building on a 25-year legacy within the cortical suspensory fixation segment, Smith+Nephew expands the family of ULTRABUTTON Adjustable Fixation Devices with the release of three new ULTRABUTTON products. With the launch of these new ULTRABUTTON Devices, Smith+Nephew now offers specialized solutions that address all grafts with all adjustable, all secure ACL fixation.
Dr. Cassandra Lee, University of California Davis commented, “With the added ULTRABUTTON QUAD, BB and TIB Devices, Smith+Nephew now provides me with a complete solution for all my ACL reconstruction needs with quick graft preparation and minimal steps. Whether the surgeon themselves or their surgical support staff performs graft preparation, these devices can help improve operating room efficiency.”
The QUADTRAC Quadriceps Tendon Harvest Guide System and the family of ULTRABUTTON Adjustable Fixation Devices that enable the UltraTRAC QUAD ACL Reconstruction technique are commercially available in the US and select countries across the world. They are part of Smith+Nephew’s expansive Reimagine reconstruction knee ligament solutions portfolio. To learn more, please visit https://www.smith-nephew.com/en/health-care-professionals/products/sports-medicine/quadtrac.
References
- Buerba RA, Boden SA, Lesniak B. Graft Selection in Contemporary Anterior Cruciate Ligament Reconstruction. JAAOS: Global Research and Reviews. 2021;5(10).
- Lund, Bent et al. “Is Quadriceps Tendon a Better Graft Choice Than Patellar Tendon? A Prospective Randomized Study.” Arthroscopy 2014; 30(5): 593-598.
- Malinowski K, Paszkowski J, Mostowy M, Goralczyk A, Laprade RF, Hermanowicz K. Quadriceps Tendon-Bone Full-Thickness Autograft: Reproducible and Easy Harvesting Technique Using Simple Surgical Tools. Arthroscopy Techniques. 2021;10(4).
- Dai W, Leng X, Wang J, Cheng J, Hu X, Ao Y. Quadriceps Tendon Autograft Versus Bone-Patellar Tendon-Bone and Hamstring Tendon Autografts for Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-analysis. Am J Sports Med. 2022;50(12):3425-3439.
- 2023 SmartTRAK US Knee Soft tissue fixation market report.
- Smith+Nephew 2022.Validation, QUADTRAC. Internal Report. 15011575 Rev A.
- Smith+Nephew 2022. QUADTRAC Marketing Claims. Internal Report. 15011572 Rev A.
- Smith+Nephew 2022.TRAC-Cutter Push-Pull Cut Force DV Protocol. Internal Report. 15011552 Rev A.
- Smith+Nephew 2022.QUAD-Cutter Force to Cut Design Verification. Internal Report. 15011559 Rev A.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 19,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew plc
